Virtus ETF Advisers LLC Purchases 2,479 Shares of Immatics (NASDAQ:IMTX)

Virtus ETF Advisers LLC boosted its position in Immatics (NASDAQ:IMTX) by 34.8% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 9,594 shares of the company’s stock after acquiring an additional 2,479 shares during the quarter. Virtus ETF Advisers LLC’s holdings in Immatics were worth $68,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors have also added to or reduced their stakes in the company. Guggenheim Capital LLC purchased a new stake in Immatics during the fourth quarter valued at about $101,000. Mitsubishi UFJ Asset Management Co. Ltd. boosted its position in Immatics by 24.6% during the fourth quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 22,701 shares of the company’s stock valued at $163,000 after buying an additional 4,477 shares during the period. Aristides Capital LLC purchased a new stake in Immatics during the fourth quarter valued at about $205,000. Y Intercept Hong Kong Ltd purchased a new stake in Immatics during the fourth quarter valued at about $211,000. Finally, Marshall Wace LLP purchased a new stake in Immatics during the fourth quarter valued at about $409,000. 64.41% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Separately, Cantor Fitzgerald reiterated an “overweight” rating on shares of Immatics in a report on Tuesday, April 1st. Four investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, the company has an average rating of “Buy” and an average price target of $16.67.

Immatics Trading Up 5.5 %

Immatics stock opened at $4.77 on Tuesday. The firm has a 50-day moving average of $4.42 and a 200-day moving average of $6.28. The firm has a market cap of $579.79 million, a P/E ratio of -7.23 and a beta of 0.85. Immatics has a 1-year low of $3.30 and a 1-year high of $13.77.

Immatics (NASDAQ:IMTX) last posted its earnings results on Thursday, March 27th. The company reported $0.48 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.03) by $0.51. The company had revenue of $15.67 million during the quarter, compared to analyst estimates of $16.16 million. Immatics had a negative net margin of 47.94% and a negative return on equity of 15.90%. Research analysts forecast that Immatics will post -0.72 earnings per share for the current fiscal year.

Immatics Profile

Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as TCR-engineered autologous or allogeneic adoptive cell therapies (ACT) and antibody-like TCR Bispecifics.